The following is a summary of “Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal ...

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

If you have psoriatic arthritis (PsA) and you’re having trouble ... sleeping and ask whether there are any new or alternative treatments that could offer some relief. Although PsA doesn ...

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...

Psoriatic arthritis (PsA) is a chronic ... Though there is no cure, there is a growing range of treatments available to help stop the disease progression, lessen pain, protect joints and preserve ...

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

AI Colton Scholar Dr. Jimin Tan earns ANRF grant to find PsA drug targets using machine learning and tissue analysis to ...

EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more ...